Corvus Pharmaceuticals (CRVS) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Pipeline and clinical development

• Lead asset soquelitinib is in a phase III trial for peripheral T-cell lymphoma and about to enter phase II for atopic dermatitis, with additional phase II proof-of-concept studies in asthma and hidradenitis suppurativa planned for this year.

• Interim analysis for the lymphoma trial is expected by year-end 2026, and the phase II atopic dermatitis trial will provide data in about 18 months.

• Soquelitinib is supported by strong intellectual property, with composition of matter protection through 2037.

• The company is also developing next-generation ITK inhibitors for broader immune and oncology indications.

Mechanism of action and differentiation

• Soquelitinib is a selective, covalent ITK inhibitor, modulating multiple inflammatory pathways upstream, unlike most therapies that target single cytokines.

• The drug spares RLK and BTK, supporting a favorable safety profile and limiting off-target effects.

• ITK inhibition leads to Th1 skewing and conversion of pro-inflammatory Th17 cells to regulatory T cells, potentially inducing durable remission.

• The mechanism allows for treatment of a broad range of Th2 and Th17-driven diseases, including atopic dermatitis, asthma, psoriasis, and fibrotic disorders.

Clinical efficacy and safety data

• In phase I trials for atopic dermatitis, soquelitinib showed 75% of patients achieving EASI-75, 25% EASI-90, and 33% IGA 0/1 after eight weeks, with a mean EASI reduction of 72%.

• Efficacy was consistent across treatment-naive and previously treated patients, including those resistant to prior systemic therapies.

• Durable responses were observed, with continued disease control after treatment cessation and no rebound effect, unlike other therapies.

• Safety profile was favorable, with no new safety signals, no significant lab abnormalities, and similar adverse events between active and placebo groups.